Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kan. Senate votes for meth precursor e-tracking

This article was originally published in The Tan Sheet

Executive Summary

A statewide system for tracking purchases of nonprescription products containing ephedrine or pseudoephedrine is a step closer to reality after the Kansas Senate passes S.B. 248. Following its March 12 approval by 37-3 margin, the bill will next be considered in the state House. Other states have set up similar electronic logbooks to monitor purchases of methamphetamine precursors - including Tennessee, which says its statewide tracking system has been a success (1"The Tan Sheet" Feb. 2, 2009, p. 4). ... Mo. Senate votes down PSE Rx amendment: An attempt to amend a larger crime bill with a measure requiring a prescription for products containing methamphetamine precursors fails in the Missouri state Senate March 4. The amendment offered by state Sen. Jason Crowell, a Republican representing the Cape Girardeau area, "was soundly defeated" by voice vote, according to a legislature spokesman. Separately, Crowell has sponsored a bill, S.B. 160, to make cough/cold remedies containing ephedrine or pseudoephedrine available by prescription only, which remains viable (2"The Tan Sheet" Feb. 23, 2009, p. 3). A companion bill, H.B. 496, is under consideration in the House and has been passed out of committee

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel